How Vertex Regained Its Footing On A Competitor's Bullish Report
Licensing
Vertex stock regained its footing Tuesday, rising on a strong second-quarter report and amid heightened expectations for its kidney disease treatment. Late Monday, competitor Otsuka unveiled promising data and bullish uptake numbers for its IgA nephropathy treatment, Voyxact, in the U.S. Voyxact works by blocking BAFF and APRIL cytokines. It's the same mechanism behind Vertex Pharmaceuticals' (VRTX) povetacicept. IgA nephropathy…
